A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma Research

Background:

• Sarcomatoid renal cell carcinoma (SRCC) presents a significant clinical challenge due to its aggressive nature and poor prognosis.
• Current treatment standards for SRCC are limited, highlighting the need for novel therapeutic strategies.
• Emerging research indicates potential efficacy of immune checkpoint inhibitors in managing advanced SRCC.

Observation:

• An 82-year-old male patient with an incidental renal tumor was diagnosed with clear cell renal cell carcinoma (RCC) with a sarcomatoid component.
• Post-nephrectomy, the patient developed extensive lung metastases, local recurrence, and peritonitis carcinomatosis, with limited response to tyrosine-kinase inhibitors.
• Intravenous administration of nivolumab, an immune checkpoint inhibitor, was initiated for the advanced metastatic disease.

Findings:

• Nivolumab treatment resulted in a gradual reduction of lung metastases, local recurrence, and peritonitis carcinomatosis.
• After 20 months of nivolumab therapy, the patient achieved a complete radiological response, with no evidence of metastatic disease on CT scans.
• This case suggests a favorable response to nivolumab in a patient with advanced, metastatic SRCC.

Implications:

• Nivolumab represents a potential therapeutic option for patients diagnosed with sarcomatoid renal cell carcinoma, particularly those with multiple metastases.
• This case underscores the role of immunotherapy in managing rare and aggressive subtypes of renal cell carcinoma.
• Further clinical investigation is warranted to establish nivolumab's efficacy and safety profile in a broader SRCC patient cohort.